Background/aims: This study compared the prognostic values of the Model for End-stage Liver Disease (MELD) and the hepatic venous pressure gradient (HVPG) in the prediction of death within 3 and 12 months in patients with decompensated liver cirrhosis.

Methods: We used data from 136 consecutive patients with decompensated cirrhosis who underwent HVPG between January 2006 and June 2008. Cox regression analysis was used to investigate the independent relationships with death of MELD and HVPG. The prognostic accuracies of MELD and HVPG were analyzed by calculating the area under the receiver operating characteristic curve (AUROC) for the occurrence of death within 3 and 12 months.

Results: Both MELD and HVPG were independent predictors of death [hazard ratio (HR)=1.11 and 1.12, respectively; 95% confidence interval (CI)=1.04~1.20 and 1.08-1.16]. Analysis of the AUROC demonstrated that the prognostic power did not differ between MELD and HVPG for predicting the 3-month survival (HR=0.76 and 0.68, respectively; 95% CI=0.62~0.89 and 0.52~0.84; P=0.22) or the 12-month survival (HR=0.72 and 0.73, 95% CI=0.61~0.83 and CI=0.61~0.84).

Conclusions: Both MELD and HVPG are independent prognostic factors of death within 3 and 12 months in patients with decompensated liver cirrhosis, and their accuracies are similar. However, HVPG has a limited role in the prediction of death in decompensated cirrhosis due to its invasiveness and limited use.

Download full-text PDF

Source
http://dx.doi.org/10.3350/kjhep.2009.15.3.350DOI Listing

Publication Analysis

Top Keywords

meld hvpg
20
patients decompensated
16
decompensated liver
12
model end-stage
8
end-stage liver
8
liver disease
8
hepatic venous
8
venous pressure
8
pressure gradient
8
hvpg
8

Similar Publications

Article Synopsis
  • Severe alcohol-associated hepatitis (SAH) is a serious condition with high mortality rates, and current treatments like corticosteroids have limited effectiveness, prompting the exploration of new therapies such as fecal microbiota transplantation (FMT).
  • This study aimed to investigate the impact of FMT on 30- and 90-day mortality in SAH patients who did not respond to or were ineligible for corticosteroids, as well as to identify outcomes and factors influencing patient survival.
  • The research involved a prospective analysis of adult patients receiving FMT, comparing their outcomes with a control group who received standard care, and evaluating various prognostic factors related to SAH outcomes.
View Article and Find Full Text PDF

Introduction: Budd-Chiari syndrome (BCS) is an uncommon disease caused by hepatic venous outflow obstruction. They can result in centrilobular fibrosis, nodular regenerative hyperplasia and cirrhosis. Assessing liver fibrosis is crucial for determining the stage of BCS, predicting disease progression and guiding treatment decisions.

View Article and Find Full Text PDF

Background And Aims: We aimed to characterise insulin-like growth factor-1 (IGF-1) signalling in patients with advanced chronic liver disease (ACLD).

Methods: Consecutive patients undergoing hepatic venous pressure gradient [HVPG] measurement were prospectively included. Clinical stages were defined as follows: probable ACLD (pACLD): liver stiffness ≥10 kPa and HVPG ≤5 mmHg, S0: mild PH (HVPG 6-9 mmHg), S1: clinically significant PH (CSPH), S2: CSPH with varices, S3: past variceal bleeding, S4: past/current non-bleeding hepatic decompensation and S5: further decompensation.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the role of histamine in advanced chronic liver disease (ACLD) and its potential as a prognostic marker.
  • It includes 251 patients with ACLD, finding that higher plasma histamine levels correlate with circulatory dysfunction, but levels do not significantly vary across different stages of liver disease.
  • Elevated histamine levels are independently associated with an increased risk of acute-on-chronic liver failure (ACLF) or liver-related death over a median follow-up of 29.2 months.
View Article and Find Full Text PDF

Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease.

Aliment Pharmacol Ther

October 2024

Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Article Synopsis
  • - The study investigated zinc and selenium deficiency in 309 patients with advanced chronic liver disease (ACLD) and found that 73% were deficient in zinc and 63% in selenium, indicating a high prevalence of these deficiencies in this population.
  • - It was observed that patients with decompensated ACLD had significantly lower levels of both trace elements compared to those with compensated ACLD, and there were strong correlations between zinc/selenium levels and disease severity indicators like MELD and HVPG.
  • - Low levels of zinc and selenium were independently associated with worsening liver-related events, including hepatic decompensation and liver-related death, suggesting that future research should explore the benefits of zinc/selenium supplementation for these patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!